Pharmacotherapy of cocaine abuse: Preclinical development
- 31 May 1994
- journal article
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 18 (1) , 121-142
- https://doi.org/10.1016/0149-7634(94)90042-6
Abstract
No abstract availableKeywords
This publication has 90 references indexed in Scilit:
- Competitive and non-competitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitizationLife Sciences, 1992
- Effects of cocaine alone and in combination with haloperidol and SCH 23390 on cardiovascular function in squirrel monkeysLife Sciences, 1991
- Effects of low, autoreceptor selective doses of dopamine agonists on the discriminative cue and locomotor hyperactivity produced by d-amphetamineJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1991
- Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the ratLife Sciences, 1991
- Noradrenergic mechanisms appear not to be involved in cocaine-induced seizures and lethalityLife Sciences, 1990
- Central mechanisms of action involved in cocaine-induced tachycardiaLife Sciences, 1990
- The effect of SCH 23390 against toxic doses of cocaine, d-amphetamine and methamphetamineLife Sciences, 1989
- Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in ratsLife Sciences, 1989
- Lethal effects of cocaine are reduced by the dopamine-1 receptor antagonist SCH 23390 but not by haloperidolLife Sciences, 1989
- Pimozide blocks establishment but not expression of cocaine-produced environment-specific conditioningLife Sciences, 1986